v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | ISRCTN26285740 |
Full text link
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
First author
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Contact
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
yogesh_dound@yahoo.com |
Registration date
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
2022-04-19 |
Recruitment status
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Not recruiting |
Study design
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
RCT |
Allocation
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Randomized |
Design
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Parallel |
Masking
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Not reported |
Center
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
single-center |
Study aim
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Prevention |
Inclusion criteria
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
1. Adult male or female human volunteer of age 18-65 years (inclusive) 2. Eligible for vaccination for COVID-19 3. Willing and able to provide written, signed and dated informed consent 4. Had no medical history or evidence of COVID-2019 5. Had no acute infections and/or respiratory diseases within 14 days before enrollment. 6. Had no evidence of vaccine-induced reactions or complications after receiving immunobiological products in the past medical history. 7. Willing to give consent to use effective contraception methods during the study 8. Have a negative urine pregnancy test at the screening visit (for child-bearing aged women) 9. Have negative human immunodeficiency virus (HIV 1 & 2), syphilis, hepatitis B and C test results |
Exclusion criteria
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
1. Aged <18 years and >65 years 2. Any vaccination/immunization within 30 days before the enrollment 3. Any treatment with steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products within 30 days before the enrollment 4. Any treatment with immunosuppressive therapy within 3 months before the enrollment 5. Any drug allergy (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on enrollment day 6. Any neoplasms in the past medical history 7. Donated blood or plasma within 3 months before the enrollment 8. Any history or evidence of splenectomy 9. Any immunodeficiency state 10. Any history or evidence of anorexia or protein deficiency of any origin 11. Alcohol or drug addiction in the past medical history 12. Participation in any other interventional clinical trial within 3 months 13. Any other condition that the study physician considers as a barrier to the trial completion as per the protocol 14. Pregnancy or breast-feeding 15. Subjects who are tested positive for Coronavirus disease through RT-PCR SARS CoV-2 Test and positive anti-COVID antibodies within 3 months before the enrollment |
Number of arms
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
2 |
Funding
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Shreepad Shree Vallabh SSV Phytopharmaceuticals |
Inclusion age min
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
18 |
Inclusion age max
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
65 |
Countries
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
India |
Type of patients
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Healthy volunteers |
Severity scale
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
N/A |
Total sample size
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
50 |
primary outcome
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Measured by blood test at baseline and 120 days: 1. Absolute lymphocyte count (CD3+; CD4+ and CD8+) 2. Anti-SARS-CoV-2 spike protein (S1 /S2) IgG |
Notes
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Phase
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Not reported |
Arms
Last imported at : April 29, 2022, 10 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
[{"arm_notes": "", "treatment_id": 2452, "treatment_name": "Curvic", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |